TRYP Therapeutics - Psilocybin Advantages You Need To Know
Tryp Therapeutics (CSE: TRYP) (OTCMKTS: TRYPF) is one of the leading psychedelic drug development companies in the industry today, and CEO and Chairman Greg McKee joins The Dales Report once again to discuss a variety of topics that directly relate to the future of psychedelics in mainstream medicinal practices.
An in-depth 20 minute conversation with Tryp Therapeutics Chairman and CEO Greg McKee helps to illuminate the opportunity available to investors today in TRYP shares.
Disclosure
Author owns shares of Tryp Therapeutics at the time of publishing and may choose to buy or sell at any time without notice.
DISCLAIMER:
The work included in this article is based on current events, technical charts, company news releases, and the author’s opinions. It may contain errors, and you shouldn’t make any investment decision based solely on what you read here. This publication contains forward-looking statements, including but not limited to comments regarding predictions and projections. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. This publication is provided for informational and entertainment purposes only and is not a recommendation to buy or sell any security. Always thoroughly do your own due diligence and talk to a licensed investment adviser prior to making any investment decisions. Junior resource and biotechnology companies can easily lose 100% of their value so read company profiles on www.sedarplus.ca for important risk disclosures. It’s your money and your responsibility.